116 results on '"Massaro, Fulvio"'
Search Results
2. Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.
3. Age-related changes in human bone marrow mesenchymal stromal cells: morphology, gene expression profile, immunomodulatory activity and miRNA expression
4. Supportive Care in Older Lymphoma Patients to Reduce Toxicity and Preserve Quality of Life
5. Germinotropic lymphoproliferative disorder: a systematic review
6. Correction to: Diagnosis and treatment of Chiari Malformation and syringomyelia in adults: International Consensus Document
7. Clinical diagnosis—part I: what is really caused by Chiari I
8. Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline
9. Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events
10. Syringomyelia Associated with Chiari 1 Malformation in Adults: Positive Outcome Predictors after Posterior Fossa Decompression with Duraplasty
11. HIGHLIGHTS FROM THE 20TH IWCLL
12. Early molecular response in chronic myeloid leukemia and halving time: Latest evidences
13. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN
14. Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC)
15. New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
16. Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
17. New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
18. Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
19. 3129 – IMPACT OF AGING ON THE BIOLOGICAL PROPERTIES OF BONE MARROW MESENCHYMAL STROMAL CELLS.
20. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience
21. Prognostic Impact of Muscle Quantity and Quality and Fat Distribution in Diffuse Large B-Cell Lymphoma Patients
22. Aging of bone marrow mesenchymal stromal cells: Hematopoiesis disturbances and potential role in the development of hematologic cancers
23. Hodgkin's lymphoma: post- autologous transplantation consolidation therapy
24. Aging of Bone Marrow Mesenchymal Stromal Cells: Hematopoiesis Disturbances and Potential Role in the Development of Hematologic Cancers
25. Management of Extramedullary Intradural Spinal Tumors: The Impact of Clinical Status, Intraoperative Neurophysiological Monitoring and Surgical Approach on Outcomes in a 12-Year Double-Center Experience
26. A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination As Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma
27. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience.
28. HL-307: A Retrospective Analysis of Brentuximab Vedotin and Pembrolizumab Combination as Salvage Treatment for Patients with Relapsed or Refractory Hodgkin Lymphoma
29. Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma
30. Retrospective evaluation of phenotype and management of a-hypo-fibrinogenemia in a cohort of Italian patients
31. Atypical cutaneous lesions in advanced-stage Hodgkin lymphoma: A case report
32. Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib
33. Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?
34. Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.
35. Ponatinib: A Review of Efficacy and Safety
36. Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?
37. Spinal melanocytoma with leptomeningeal spread and long survival following surgery and chemotherapy
38. Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy
39. Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib
40. Investigation of possible correlation between clinical and laboratory phenotype in congenital FXI deficiency: results from a single center
41. The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials
42. Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update
43. Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib
44. How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes
45. Second line small molecule therapy options for treating chronic myeloid leukemia
46. Incidence of Severe (≤ 10g/dl) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy
47. Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis
48. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN
49. Current first- and second-line treatment options in acute promyelocytic leukemia
50. Unusual Bulky Presentation due to Missed Diagnosis of Hodgkin Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.